beluuga.ai

Overview

Pharmaceutical

STELLA PHARMA CORPORATION

Stella Pharma is a Japanese pharmaceutical company focused on the development and commercialization of Boron Neutron Capture Therapy (BNCT), a targeted radiation treatment that selectively destroys cancer cells. The company's flagship product, Steboronine® (SPM-011), received world-first regulatory approval in Japan in March 2020 as a boron drug for BNCT, indicated for unresectable locally advanced or locally recurrent head and neck cancer. The company is pursuing pipeline expansion into additional oncology indications, including recurrent malignant glioma, in partnership with accelerator manufacturers under a combination product model.

Market Cap

¥14.3B

US$91.0M

¥11.4B

US$72.5M

Stock¥396▼-2.70%

US$1 = ¥156.80 (2026-10-23)

LTM EV/EBITDA

LTM EV/EBIT

LTM PER

LTM PBR

4.4

Stock vs TOPIX (1Y, base=100)vs TOPIX ▲+0.5%pt

Oct 24, 25 – Oct 23, 26StockTOPIX

1Jan 6, 26Hisamitsu pharma MBO announcement sector rally

2Feb 18, 26Continued pharma M&A expectations

3Mar 24, 26Taisho Pharma ¥710bn MBO announcement impact

4Oct 8, 26Stebolonine for recurrent meningioma to be reviewed by Pharmaceutical Affairs Council

MC → EV Bridge

AI Briefing

Generating insights…

Performance & Balance

Revenue 5Y (¥B)

EBITDA 5Y (¥B)

Net Income 5Y (¥B)

Capital Structure

78%

22%

EquityD/E 0.28xDebt

Liquidity vs Debt 5Y (¥B)▲ Net Cash

CashInv. Sec.Debt

Shareholders

Top 10 hold 46.1%

as of 2026-03-31 · Source: Annual Securities Report

STELLA CHEMIFA CORPORATION

33.66%

Takuji NAKAMURA

3.48%

Morgan Stanley MUFG Securities Co., Ltd.

1.51%

International Club Foundation (General Incorporated Foundation)

1.47%

Yoshiki MURAKAMI

1.38%

JPMorgan Securities Japan Co., Ltd.

1.09%

BNY Mellon SA/NV (BNY Mellon Group Client Account) (Standing Proxy: MUFG Bank, Ltd.)

1.09%

Hideyo AOYAMA

0.93%

Kaoru AOYAMA

0.89%

Nomura Securities Co., Ltd.

0.64%

Management

7 officers

Koki UEHARA

Representative Director, President

Apr 2003 Joined Stella Chemifa Corporation Aug 2007 Joined the Company; Head of R&D Department Apr 2012 Director, Head of R&D Department Nov 2012 Director, Head of Development Division; concurrently Head of Safety Management Department Feb 2015 Managing Director, Head of Development Division; concurrently Head of Safety Management Department Jun 2019 Managing Director, Head of Development Division Jun 2020 Representative Director, President (current)

1977-06-11

Kazumitsu YABU

Director

Apr 1981 Joined Hashimoto Chemical Industries Co., Ltd. (now Stella Chemifa Corporation) Jun 2003 Director, Head of Sales Department, at the same company Sep 2007 Director, Managing Executive Officer, Head of Sales Department, at the same company May 2008 Director, Managing Executive Officer, Head of Sales Division, at the same company Apr 2010 Director, Managing Executive Officer, General Manager of Sales, at the same company Oct 2013 Director, Senior Managing Executive Officer, General Manager of Sales, at the same company Apr 2015 Representative Director, Chairman of the Company Jun 2020 Director (current)

1959-01-20

Toshimitsu HAYASHI

Director

Apr 2006 Joined Shinnihon Kagaku Co., Ltd. Mar 2011 Joined the Company Jun 2014 Head of Clinical Development Department Jun 2017 Head of Clinical Promotion Department Feb 2018 Head of Regulatory Affairs Department Jun 2020 Executive Officer, Head of Regulatory Affairs Department Jun 2022 Director, Head of Regulatory Affairs Department Sep 2022 Director, Head of Regulatory Affairs Department and Head of Clinical Development Department (current)

1981-01-20

Takahiro KIDO

Director

Apr 1997 Joined Mitsui & Co., Ltd. Apr 2016 Deputy General Manager, Overseas Business Promotion Office, Business Development Division, Mitsui & Co., Ltd. Jul 2017 Chief Manager, Strategic Planning Department, Mitsui & Co. (China) Ltd. Oct 2018 Joined the Company; Executive Officer, Head of Corporate Planning Department Jun 2022 Director, Head of Corporate Planning Department (current)

1973-04-12

Masaya ONISHI

Director (Audit and Supervisory Committee Member)

Oct 1997 Joined Deloitte Touche Tohmatsu Aug 2006 Opened Masaya Onishi Certified Public Accountant and Tax Accountant Office Mar 2016 Auditor of the Company Jun 2018 Director (Audit and Supervisory Committee Member) (current) Nov 2019 Outside Director (Audit and Supervisory Committee Member), Axas Holdings Co., Ltd. (current) Apr 2022 Established Onishi Nakano Tax Accountant Corporation; Head of Office (current)

1974-05-14

Kohei TSUJII

Director (Audit and Supervisory Committee Member)

Oct 2005 Joined Midosuji Law Office, Attorney Corporation Jan 2014 Partner, Midosuji Law Office, Attorney Corporation (current) Jun 2018 Director (Audit and Supervisory Committee Member) (current)

1978-08-03

Yoshiyuki FUKUCHI

Director (Audit and Supervisory Committee Member)

Oct 2003 Joined Tokyo Hokuto Audit Corporation (now Gyosei Audit Corporation) Apr 2006 Joined Deloitte Touche Tohmatsu Sep 2018 Established Fukuchi Accounting and Tax Office; Head of Office (current) Jun 2024 Director (Audit and Supervisory Committee Member) (current)

1975-06-04

Large Shareholding Reports